Research map: Heterologous prime-boost vaccination against H5 avian influenza: Safety and immunogenicity of a MF59-adjuvanted, cell-culture derived H5N6 vaccine

Back to the article

Papers in this map

  1. The biology of influenza viruses · Nicole M. Bouvier · 2008 · 1240 citations · Cited by this paper
  2. The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions · Chalothorn Wannaphut · 2026 · Related
  3. Influenza Virus Evolution, Host Adaptation, and Pandemic Formation · Jeffery K. Taubenberger · 2010 · 973 citations · Cited by this paper
  4. Pneumococcal vaccination awareness and uptake among high-risk patients attending internal medicine outpatient clinics: A cross-sectional study · 2026 · Related
  5. Mechanisms of Action of Adjuvants · Sunita Awate · 2013 · 752 citations · Cited by this paper
  6. Route of BCG administration determines success · 2026 · Related
  7. Immune boosting by B.1.1.529 ( Omicron) depends on previous SARS-CoV-2 exposure · Catherine J. Reynolds · 2022 · 371 citations · Cited by this paper
  8. Safety monitoring of bivalent, quadrivalent, and 9-valent human papillomavirus vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study · 2026 · Related
  9. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes · Claudia P. Arevalo · 2022 · 369 citations · Cited by this paper
  10. Immunological insights into why pertussis continues to be endemic · 2026 · Related
  11. Adjuvanted influenza vaccines · John S. Tregoning · 2017 · 267 citations · Cited by this paper
  12. Vaccination coverage and influencing factors of four non‑National Immunization Program vaccines: A cross‑sectional survey among children aged 1‒6 years in Beijing, China · 2026 · Related
  13. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine · Grazia Galli · 2009 · 266 citations · Cited by this paper
  14. Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan’s pediatric National Immunization Program and impacts of a delayed implementation · 2026 · Related
  15. Adjuvanted H5N1 vaccine induces early CD4 + T cell response that predicts long-term persistence of protective antibody levels · Grazia Galli · 2009 · 262 citations · Cited by this paper
  16. Budget impact analysis of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccination for preventing respiratory syncytial virus in Egyptian infants · 2026 · Related
  17. MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults · Angelika Banzhoff · 2009 · 195 citations · Cited by this paper
  18. Health-related quality of life and adverse events during 14 days after receiving a live-attenuated influenza vaccine in Japanese children 4–15 years of age · 2026 · Related
  19. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects · Sharon E. Frey · 2014 · 146 citations · Cited by this paper
  20. Spatial accessibility analysis of vaccination units in Gansu Province, China (2025) · 2026 · Related
  21. Identification of Low- and High-Impact Hemagglutinin Amino Acid Substitutions That Drive Antigenic Drift of Influenza A(H1N1) Viruses · William T. Harvey · 2016 · 84 citations · Cited by this paper
  22. Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories · Mary E. Zacour · 2016 · 82 citations · Cited by this paper
  23. Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses · Isabella Alberini · 2009 · 70 citations · Cited by this paper
  24. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children · Terry M. Nolan · 2014 · 55 citations · Cited by this paper
  25. Comparison of influenza-specific neutralizing antibody titers determined using different assay readouts and hemagglutination inhibition titers: good correlation but poor agreement · Federica Sicca · 2020 · 42 citations · Cited by this paper
  26. Pandemic Influenza Vaccines: What did We Learn from the 2009 Pandemic and are We Better Prepared Now? · Steven P. Rockman · 2020 · 27 citations · Cited by this paper
  27. Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study · Joanna Waldock · 2023 · 26 citations · Cited by this paper
  28. Immune Escape Adaptive Mutations in Hemagglutinin Are Responsible for the Antigenic Drift of Eurasian Avian-Like H1N1 Swine Influenza Viruses · Chengzhi Xu · 2022 · 21 citations · Cited by this paper
  29. Safety and Immunogenicity of MF59-Adjuvanted Cell Culture–Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly · Sharon E. Frey · 2019 · 17 citations · Cited by this paper
  30. Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects · Pornthep Chanthavanich · 2019 · 12 citations · Cited by this paper
  31. Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis · Alexander Domnich · 2024 · 12 citations · Cited by this paper
  32. Are Microneutralization and Hemagglutination Inhibition Assays Comparable? Serological Results from Influenza Experimentally Infected Mallard Ducks · Karen M. Segovia · 2018 · 10 citations · Cited by this paper
  33. Pandemic preparedness: On the efficacy of non‐pharmaceutical interventions in COVID‐19 and about approaches to predict future pandemic viruses · Harald Brüssow · 2024 · 10 citations · Cited by this paper
  34. Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults · Eve M. Versage · 2021 · 9 citations · Cited by this paper
  35. Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience · Steven P. Rockman · 2022 · 9 citations · Cited by this paper
  36. Epitope Variation in Hemagglutinin and Antibody Responses to Successive A/Victoria A(H1N1) Strains in Young and Older Adults Following Seasonal Influenza Vaccination: A Pilot Study · Mónica Espinar-García · 2025 · 6 citations · Cited by this paper
  37. Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects · James T. Peterson · 2022 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)